MVMarine Villard

Marine Villard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marine Villard has a total of 56 co-authors. Here are the top co-authors by number of shared publications:

  • Jérôme Honnorat

    Université Lyon 1, Hospices Civils de Lyon, INSERM, CNRS, French Reference Center on Paraneoplastic Neurological Diseases and Autoimmune Encephalitis, UMR MELIS Inserm 1314/CNRS 5284, France

    4 shared publications
  • Véronique Rogemond

    Centre de Référence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Auto-immunes, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France

    4 shared publications
  • Alberto Vogrig

    Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy; Department of Medicine (DMED), University of Udine, Udine, Italy

    3 shared publications
  • Bastien Joubert

    French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France

    3 shared publications
  • Geraldine Picard

    French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France

    3 shared publications
  • Macarena Villagrán-García

    French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France

    3 shared publications

Latest Publications

  • Open Access

    Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes

    by Elise Peter, Isabelle Treilleux, Valentin Wucher, Macarena Villagrán-García, Pauline Dumez, Daniel Pissaloux, Sandrine Paindavoine, Valéry Attignon, Geraldine Picard, Veronique Rogemond, et al.

    Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS). Using clinicopathologic data, DNA sequencing, and whole-transcriptome analysis, 28 BCs associated with Ri-PNS were characterized regarding oncological characteristics. Genetic alteration of the onconeural antigens and differential gene expression profiles were analyzed in the 12 available tumor samples and compared with those of 5 Yo-PNS tumors. Ri-PNS BCs were mainly luminal B invasive carcinomas that did not overexpress HER2 and were a subtype of BCs different from the ones observed in Yo-PNS BCs. They had a low expression of wild-type TP53 and deletions of 1p chromosome. Neither overexpression nor genetic alteration of the Ri onconeural antigens was found in Ri-PNS BCs. Conversely, the nature of the antitumor immune reaction in Ri-PNS BCs was similar to the one found in Yo-PNS BCs. Ri-BCs also had a high propension for early nodal regional metastasis. BCs associated with Ri-PNS are uncommon and the tumor subtype and their molecular and oncological characteristics are different from those of Yo-PNS and controls. Overexpression or sequence variation in the gene of the onconeural antigen is not mandatory. Conversely, Ri-PNS-associated and Yo-PNS-associated BCs display the same atypical B-cell-mediated intratumoral immune response, and tumor escape in the lymph nodes is frequent.


  • Open Access

    Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies

    by Florian Lamblin, Jeroen Kerstens, Sergio Muñiz-Castrillo, Alberto Vogrig, David Goncalves, Veronique Rogemond, Geraldine Picard, Marine Villard, Anne-Laurie Pinto, Marleen H. Van Coevorden-Hameete, et al.

    While patients with paraneoplastic autoimmune encephalitis (AE) with gamma-aminobutyric-acid B receptor antibodies (GABABR-AE) have poor functional outcomes and high mortality, the prognosis of nonparaneoplastic cases has not been well studied. Patients with GABABR-AE from the French and the Dutch Paraneoplastic Neurologic Syndromes Reference Centers databases were retrospectively included and their data collected; the neurologic outcomes of paraneoplastic and nonparaneoplastic cases were compared. Immunoglobulin G (IgG) isotyping and human leukocyte antigen (HLA) genotyping were performed in patients with available samples. A total of 111 patients (44/111 [40%] women) were enrolled, including 84 of 111 (76%) paraneoplastic and 18 of 111 (16%) nonparaneoplastic cases (cancer status was undetermined for 9 patients). Patients presented with seizures (88/111 [79%]), cognitive impairment (54/111 [49%]), and/or behavioral disorders (34/111 [31%]), and 54 of 111 (50%) were admitted in intensive care unit (ICU). Nonparaneoplastic patients were significantly younger (median age 54 years [range 19-88] vs 67 years [range 50-85] for paraneoplastic cases, p < 0.001) and showed a different demographic distribution. Nonparaneoplastic patients more often had CSF pleocytosis (17/17 [100%] vs 58/78 [74%], p = 0.02), were almost never associated with KTCD16-abs (1/16 [6%] vs 61/70 [87%], p < 0.001), and were more frequently treated with second-line immunotherapy (11/18 [61%] vs 18/82 [22%], p = 0.003). However, no difference of IgG subclass or HLA association was observed, although sample size was small (10 and 26 patients, respectively). After treatment, neurologic outcome was favorable (mRS ≤2) for 13 of 16 (81%) nonparaneoplastic and 37 of 84 (48%) paraneoplastic cases (p = 0.03), while 3 of 18 (17%) and 42 of 83 (51%) patients had died at last follow-up (p = 0.008), respectively. Neurologic outcome no longer differed after adjustment for confounding factors but seemed to be negatively associated with increased age and ICU admission. A better survival was associated with nonparaneoplastic cases, a younger age, and the use of immunosuppressive drugs. Nonparaneoplastic GABABR-AE involved younger patients without associated KCTD16-abs and carried better neurologic and vital prognoses than paraneoplastic GABABR-AE, which might be due to a more intensive treatment strategy. A better understanding of immunologic mechanisms underlying both forms is needed.


  • Open Access

    Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis

    by Lucia Campetella, Antonio Farina, Macarena Villagrán-García, Marine Villard, Marie Benaiteau, Noémie Timestit, Alberto Vogrig, Géraldine Picard, Véronique Rogemond, Dimitri Psimaras, et al.

    Relapses occur in 15%-25% of patients with leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) autoimmune encephalitis and may cause additional disability. In this study, we clinically characterized the relapses and identified factors predicting their occurrence. This is a retrospective chart review of patients with LGI1-Ab encephalitis diagnosed at our center between 2005 and 2022. Relapse was defined as worsening of previous or appearance of new symptoms after at least 3 months of clinical stabilization. Among 210 patients, 30 (14%) experienced a total of 33 relapses. The median time to first relapse was 23.9 months (range: 4.9-110.1, interquartile range [IQR]: 17.8). The CSF was inflammatory in 11/25 (44%) relapses, while LGI1-Abs were found in the serum in 16/24 (67%) and in the CSF in 12/26 (46%); brain MRI was abnormal in 16/26 (62%) relapses. Compared with the initial episode, relapses manifested less frequently with 3 or more symptoms (4/30 patients, 13% vs 28/30, 93%; p < 0.001) and had lower maximal modified Rankin scale (mRS) score (median 3, range: 2-5, IQR: 1 vs 3, range: 2-5, IQR: 0; p = 0.001). The median mRS at last follow-up after relapse (2, range: 0-4, IQR: 2) was significantly higher than after the initial episode (1, range: 0-4, IQR: 1; p = 0.005). Relapsing patients did not differ in their initial clinical and diagnostic features from 85 patients without relapse. Nevertheless, residual cognitive dysfunction after the initial episode (hazard ratio:13.8, 95% confidence interval [1.5; 129.5]; p = 0.022) and no administration of corticosteroids at the initial episode (hazard ratio: 4.8, 95% confidence interval [1.1; 21.1]; p = 0.036) were significantly associated with an increased risk of relapse. Relapses may occur years after the initial encephalitis episode and are usually milder but cause additional disability. Corticosteroid treatment reduces the risk of future relapses, while patients with residual cognitive dysfunction after the initial episode have an increased relapse risk.


  • Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review

    by Macarena Villagrán-García, Sergio Muñiz-Castrillo, Nicolás Lundahl Ciano-Petersen, Alberto Vogrig, Antonio Farina, Marine Villard, Dimitri Psimaras, Agusti Alentorn, David Gonçalves, Nicole Fabien, et al.

    Background The link between paraneoplastic neurological syndromes (PNS) and renal cell and bladder cancer (RCC/BC) is rare and uncertain. Our aim was to clinically evaluate, in light of the updated PNS criteria, these uncommon associations. Methods Retrospective nationwide cohort chart review study and systematic review of the literature. Results After excluding 5 patients due to the diagnosis of another co-occurrent malignancy, 10/18 patients with RCC and 8/18 patients with BC were identified. A total of 31 cases were previously published, yielding an overall series of 27/49 RCC and 22/49 BC patients. There was a predominance of cerebellar syndromes in both cancers (10/27, 37% for RCC; 9/22, 41% for BC), followed by encephalitis in 9/27 (33%) patients with RCC and encephalomyelitis/sensory neuronopathy in 5/22 (23%) patients with BC. The detection of high-risk Abs was more frequent among BC patients (16/19, 84% vs. 3/13, 23% in RCC, p = 0.0009), Ri antibodies being the most frequent thereof. After applying the updated PNS criteria, patients with BC met highest degrees (possible, probable, and definite) of certainty for PNS diagnosis (20/22, 91% vs. 16/27, 59% in RCC, p = 0.021). Conclusion A second neoplasm should always be ruled out before establishing the diagnosis of PNS in patients with RCC or BC. However, while this association remains dubious for most patients with RCC, a casual role is more probable in patients with BC and high-risk antibodies presenting with cerebellar ataxia, brainstem encephalitis or encephalomyelitis/sensory neuronopathy.